# Efficacy of Naloxone in Reducing Postictal Central Respiratory Dysfunction in Patients With Epilepsy

> **NCT02332447** · PHASE3 · COMPLETED · sponsor: **Hospices Civils de Lyon** · enrollment: 485 (actual)

## Conditions studied

- Epilepsy

## Interventions

- **DRUG:** naloxone
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02332447
- **Lead sponsor:** Hospices Civils de Lyon
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06-26
- **Primary completion:** 2020-07-30
- **Final completion:** 2020-07-30
- **Target enrollment:** 485 (ACTUAL)
- **Last updated:** 2025-09-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02332447

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02332447, "Efficacy of Naloxone in Reducing Postictal Central Respiratory Dysfunction in Patients With Epilepsy". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02332447. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*